Tipifarnib in Treating Patients With Myelodysplastic Syndromes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of tipifarnib in treating patients
with myelodysplastic syndromes. Tipifarnib may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth.